Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.

Krauwinkel WJ, Kerbusch VM, Meijer J, Tretter R, Strabach G, Van Gelderen EM

Open source

DOI
10.1002/cpdd.37
Published
2013 Jul
Container
Clinical pharmacology in drug development
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cpdd.37,
  title = {Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.},
  author = {Krauwinkel WJ and Kerbusch VM and Meijer J and Tretter R and Strabach G and Van Gelderen EM},
  year = {2013},
  journal = {Clinical pharmacology in drug development},
  doi = {10.1002/cpdd.37},
  url = {https://doi.org/10.1002/cpdd.37}
}

RIS

TY  - JOUR
TI  - Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.
AU  - Krauwinkel WJ
AU  - Kerbusch VM
AU  - Meijer J
AU  - Tretter R
AU  - Strabach G
AU  - Van Gelderen EM
PY  - 2013
JO  - Clinical pharmacology in drug development
DO  - 10.1002/cpdd.37
UR  - https://doi.org/10.1002/cpdd.37
ER  - 

APA

WJ, K., VM, K., J, M., R, T., G, S., & EM, V. G. (2013). Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.. Clinical pharmacology in drug development. https://doi.org/10.1002/cpdd.37

Source records